6S4I

Crystal structure of zinc free A14E, B25H, B29K(N(eps)-[2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl]), desB30 human insulin

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.51 Å
  • R-Value Free: 0.212 
  • R-Value Work: 0.180 
  • R-Value Observed: 0.182 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history. 


Literature

Molecular engineering of safe and efficacious oral basal insulin.

Hubalek, F., Refsgaard, H.H.F., Gram-Nielsen, S., Madsen, P., Nishimura, E., Munzel, M., Brand, C.L., Stidsen, C.E., Claussen, C.H., Wulff, E.M., Pridal, L., Ribel, U., Kildegaard, J., Porsgaard, T., Johansson, E., Steensgaard, D.B., Hovgaard, L., Glendorf, T., Hansen, B.F., Jensen, M.K., Nielsen, P.K., Ludvigsen, S., Rugh, S., Garibay, P.W., Moore, M.C., Cherrington, A.D., Kjeldsen, T.

(2020) Nat Commun 11: 3746-3746

  • DOI: 10.1038/s41467-020-17487-9
  • Primary Citation of Related Structures:  
    6S4J, 6S4I

  • PubMed Abstract: 

    • Recently, the clinical proof of concept for the first ultra-long oral insulin was reported, showing efficacy and safety similar to subcutaneously administered insulin glargine. Here, we report the molecular engineering as well as biological and pharmacol ...

    Recently, the clinical proof of concept for the first ultra-long oral insulin was reported, showing efficacy and safety similar to subcutaneously administered insulin glargine. Here, we report the molecular engineering as well as biological and pharmacological properties of these insulin analogues. Molecules were designed to have ultra-long pharmacokinetic profile to minimize variability in plasma exposure. Elimination plasma half-life of ~20 h in dogs and ~70 h in man is achieved by a strong albumin binding, and by lowering the insulin receptor affinity 500-fold to slow down receptor mediated clearance. These insulin analogues still stimulate efficient glucose disposal in rats, pigs and dogs during constant intravenous infusion and euglycemic clamp conditions. The albumin binding facilitates initial high plasma exposure with a concomitant delay in distribution to peripheral tissues. This slow appearance in the periphery mediates an early transient hepato-centric insulin action and blunts hypoglycaemia in dogs in response to overdosing.

    Organizational Affiliation: 

    Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark. ThK@novonordisk.com.



Macromolecules
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Insulin A21Homo sapiensMutation(s): 1 
Gene Names: INS
Find proteins for P01308 (Homo sapiens)
Explore P01308 
Go to UniProtKB:  P01308
NIH Common Fund Data Resources
PHAROS:  P01308
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by: 
(by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Insulin B29Homo sapiensMutation(s): 1 
Gene Names: INS
Find proteins for P01308 (Homo sapiens)
Explore P01308 
Go to UniProtKB:  P01308
NIH Common Fund Data Resources
PHAROS:  P01308
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
NO3
Query on NO3
Download Ideal Coordinates CCD File 
B
NITRATE ION
N O3
NHNBFGGVMKEFGY-UHFFFAOYSA-N		 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.51 Å
  • R-Value Free: 0.212 
  • R-Value Work: 0.180 
  • R-Value Observed: 0.182 
  • Space Group: I 21 3
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 77.482α = 90
b = 77.482β = 90
c = 77.482γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
SCALEPACKdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report


View more in-depth experimental data

Entry History 

Deposition Data

  • Deposited Date: 2019-06-28 
  • Released Date: 2020-07-15 
    • Deposition Author(s): Johansson, E.

Revision History 

  • Version 1.0: 2020-07-15
    Type: Initial release
  • Version 1.1: 2020-08-12
    Changes: Database references